Table 1.

Tumors selected for DNA sequencing strategies, based on clinical response^a

WESb (n= 51)		Docetaxel responder		Docetaxel non-responder		Docetaxel not evaluable
		CR	PR	SD	PD
Epirubicin responder	CR					2 (1)
	PR	2 (1)	6 (3)	13 (4)	2 (0)
Epirubicin non-responder	SD		8 (1)	15 (0)
	PD			2 (1)	1 (0)
Ampliconc (n= 45)		Docetaxel responder		Docetaxel non-responder		Docetaxel not evaluable
		CR	PR	SD	PD
Epirubicin responder	CR					1 (0)
	PR	4 (0)	2 (0)	9 (1)	2 (1)
Epirubicin non-responder	SD	1 (0)	3 (1)	21 (0)	1 (0)	1 (0)
	PD

Numbers in paratheses indicate patients with pCR at surgery

^aTumors selected as response outliers (response per RECIST) and with tumor tissue available for DNA extraction (n = 96/109)

^bWES whole exome sequencing

^cAmplicon: amplicon-based sequencing of 6-gene panel